2019 FUNDED PROJECTS
Grant applications are processed through EB Research Partnership USA and are open biannually, in January and July. We award funding on the advice of the independant Scientific Advisory Board to competitive and innovative research projects with the potential to lead to commercially feasible products and therapies to treat and cure EB.
| INSTITUTION | PROJECT NAME | PRINCIPAL INVESTIGATOR(S) | AMOUNT AWARDED |
|---|---|---|---|
| Columbia University | Development of a drug testing platform for recessive dystrophic epidermolysis bullosa squamous cell carcinoma using induced pluripotent cancer cells | Joanna Jackow PhD | $551,250 |
| Neem Biotech Limited | Identification of ajoene analogues for the treatment of epidermolysis bullosa | Tracy Nevitt PhD | $112,400 |
| Thomas Jefferson University | Targeting fibrosis for RDEB therapy in preclinical animal models | Andrew South PhD | $159,054 |
| University of Colorado | A Comprehensive Stem Cell Biobank for EB Patients | Ganna Bilousova PhD Anna L. Bruckner MD Dennis R Roop PhD Igor Kogut PhD |
$286,815 |
| University of Minnesota |
Next Generation Genome Editing for RDEB |
Jakub Tolar MD PhD |
$1,000,000 |
| University of Colorado |
A cGMP-Compliant Library Master Cell Bank as a Necessary Prerequisite for an iPSC-Based Clinical Trial for EB | Igor Kogut PhD Ganna Bilousova PhD Dennis R Roop PhD |
$964,176 |
| University of Colorado | Developing an iPS Cell-based Therapy for Epidermolysis Bullosa Simplex |
Dennis R Roop PhD Ganna Bilousova PhD Igor Kogut PhD Anna Bruckner MD |
$518,638 |
| Université du Québec à Chicoutimi | Inactivation of epidermolysis bullosa simplex dominant mutations by allele-specific CRISPR/Cas9 |
Catherine Laprise PhD Lucie Germain PhD Jacques-P Tremblay PhD |
$255,400 |
| Wings Therapeutics |
Clinical Development of QR-313 for treatment of DEB |
Mark De Souza, PhD | $1,500,000 |
| University of Southern California |
Optimization of Intravenous Gentamicin Treatment to Restore Functional Laminin 332 in JEB Patients with Nonsense Mutations |
Mei Chen PhD David Woodley MD |
$254,300 |
| Stanford University |
Topical and intradermal recombinant type VII collagen protein replacement therapy for recessive dystrophic epidermolysis bullosa: A placebo controlled Phase 1 clinical trial |
M. Peter Marinkovich MD Jean Tang MD PhD David Olsen PhD Gerhard Bauer PhD |
$350,000 |
| Stanford University |
DISCOVER-JEB study for demystifying the causes of early lethality in generalized-severe Junctional Epidermolysis Bullosa due to Laminin-332 mutations |
M. Peter Marinkovich MD Vamsi Krishna Yenamandra MD PhD Irina Gurevich PhD Kerriann M Casey DVM DACVP |
$127,000 |
| Stanford University |
Computational Drug Repurposing for Epidermolysis Bullosa Simplex | Joyce Teng MD PhD Kavita Sarin MD PhD |
$187,782 |
| Centre for Human Genetics | Development of a Registry for Epidermolysis Bullosa in India |
Ravi Hiremagalore MD, Gurudatta Baraka PhD Arun Inamadar MD Sacchidanand MD |
$35,620 |
| University College Dublin | Development of gene-editing therapy to restore Type VII Collagen for the treatment of RDEB using a topical RNP CRISPR system | Wenxin Wang PhD | $117,053.44 |
| Thomas Jefferson University | Epidermolysis Bullosa Community Cell Bank | Andrew South PhD | $151,651 |
| Stanford University | GMP Manufacturing of Autologous Esophageal Epithelial cells for the Prevention of Esophageal Strictures | Anthony Oro MD PhD | $300,421 |
| FIBRX Derm | Development of Human Recombinant Decorin Core Protein as a Topical Anti-Scarring Therapy for Dystrophic Epidermolysis Bullosa | Professor Jean Tang, MD, PhD | $1,250,000 |